Covariate | Hazard ratio (95% CI)* | P Value | |
---|---|---|---|
Overall survival | |||
Gender | (male vs. females) | 0.97 (0.74-1.28) | 0.84 |
Age | (per year) | 1.004 (0.99-1.02) | 0.49 |
Duration of Disease | (per year) | 0.98 (0.94-1.02) | 0.30 |
Previous Surgery | (vs. no surgery) | 0.62 (0.45-0.84) | 0.002 |
Previous Systemic Therapies | (vs. no systemic therapies) | 1.48 (1.08-2.01) | 0.014 |
Previous Radiation | (vs. no radiation) | 0.93 (0.64-1.36) | 0.71 |
Single Metastasis | (vs. multiple metastases) | 0.66 (0.26-1.35) | 0.26 |
Liver Metastases | (vs. no liver metastases) | 1.45 (0.86-2.44) | 0.17 |
Bone Metastases | (vs. no bone metastases) | 1.57 (1.10-2.23) | 0.013 |
Tumor Uptake Score 2 | (vs. Uptake Score 1) | 0.70 (0.31-1.61) | 0.40 |
Tumor Uptake Score 3 | (vs. Uptake Score 1) | 0.40 (0.18-0.91) | 0.028 |
Low Dose [90Y-DOTA]-TOC | (vs. High Dose) | 0.40 (0.17-0.93) | 0.03 |
Intermediate Dose [90Y-DOTA]-TOC | (vs. High Dose) | 0.64 (0.38-1.06) | 0.08 |
Severe Kidney Toxicity | |||
Gender | (male vs. females) | 0.62 (0.33-1.18) | 0.14 |
Age | (per 10 years) | 0.99 (0.96-1.02) | 0.64 |
Baseline Glomerular Filtration Rate | (per 10 mL/min/1.73 m 2 ) | 1.23 (1.09-1.39) | 0.001 |
Low Dose [90Y-DOTA]-TOC | (vs. High Dose) | 0.54 (0.20-1.43) | 0.21 |
Intermediate Dose [90Y-DOTA]-TOC | (vs. High Dose) | 0.32 (0.11-0.88) | 0.027 |